Charles River Laboratories International, Inc. Stock
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
228.4 USD | +0.13% | -2.92% | -3.38% |
Financials (USD)
Sales 2024 * | 4.22B | Sales 2025 * | 4.53B | Capitalization | 11.75B |
---|---|---|---|---|---|
Net income 2024 * | 406M | Net income 2025 * | 513M | EV / Sales 2024 * | 3.24 x |
Net Debt 2024 * | 1.94B | Net Debt 2025 * | 1.46B | EV / Sales 2025 * | 2.92 x |
P/E ratio 2024 * |
28.9
x | P/E ratio 2025 * |
23.4
x | Employees | 21,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.11% |
Latest transcript on Charles River Laboratories International, Inc.
1 day | +0.13% | ||
1 week | -2.92% | ||
Current month | -0.26% | ||
1 month | -5.36% | ||
3 months | +3.71% | ||
6 months | +34.34% | ||
Current year | -3.38% |
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 73 | 75-12-31 |
Flavia Pease
DFI | Director of Finance/CFO | 51 | 22-04-24 |
Birgit Girshick
COO | Chief Operating Officer | 54 | 89-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Massaro
BRD | Director/Board Member | 76 | 02-12-31 |
Virginia Wilson
BRD | Director/Board Member | 68 | 19-09-30 |
Robert Bertolini
BRD | Director/Board Member | 61 | 11-01-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.05% | 1 M€ | -2.17% | - | |
2.07% | 5 M€ | -1.80% | - | |
1.08% | 0 M€ | 0.00% | - | |
0.98% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 228.4 | +0.13% | 447,273 |
24-05-10 | 228.1 | -0.86% | 842,499 |
24-05-09 | 230.1 | -2.21% | 1,004,419 |
24-05-08 | 235.3 | -0.43% | 610,321 |
24-05-07 | 236.3 | +0.44% | 473,892 |
Delayed Quote Nyse, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.38% | 11.75B | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
+20.21% | 11.72B |
- Stock Market
- Equities
- CRL Stock